CN106995445B - 一种布鲁顿酪氨酸激酶抑制剂晶型及其制备方法 - Google Patents
一种布鲁顿酪氨酸激酶抑制剂晶型及其制备方法 Download PDFInfo
- Publication number
- CN106995445B CN106995445B CN201610045061.9A CN201610045061A CN106995445B CN 106995445 B CN106995445 B CN 106995445B CN 201610045061 A CN201610045061 A CN 201610045061A CN 106995445 B CN106995445 B CN 106995445B
- Authority
- CN
- China
- Prior art keywords
- degrees
- crystallization
- crystal form
- hours
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610045061.9A CN106995445B (zh) | 2016-01-22 | 2016-01-22 | 一种布鲁顿酪氨酸激酶抑制剂晶型及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610045061.9A CN106995445B (zh) | 2016-01-22 | 2016-01-22 | 一种布鲁顿酪氨酸激酶抑制剂晶型及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106995445A CN106995445A (zh) | 2017-08-01 |
CN106995445B true CN106995445B (zh) | 2021-08-03 |
Family
ID=59428248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610045061.9A Active CN106995445B (zh) | 2016-01-22 | 2016-01-22 | 一种布鲁顿酪氨酸激酶抑制剂晶型及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106995445B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103694241A (zh) * | 2013-11-27 | 2014-04-02 | 苏州晶云药物科技有限公司 | Pci-32765的新晶型a及其制备方法 |
CN103923084A (zh) * | 2014-01-29 | 2014-07-16 | 苏州晶云药物科技有限公司 | 几种新晶型及其制备方法 |
CN104736178A (zh) * | 2012-06-04 | 2015-06-24 | 药品循环公司 | 布鲁顿酪氨酸激酶抑制剂的晶形 |
WO2015145415A2 (en) * | 2014-03-27 | 2015-10-01 | Perrigo Api Ltd. | Ibrutinib solid forms and production process therefor |
CN105085529A (zh) * | 2014-05-15 | 2015-11-25 | 广东东阳光药业有限公司 | 依鲁替尼新晶型及其制备方法 |
CN109776543A (zh) * | 2017-11-14 | 2019-05-21 | 上海医药工业研究院 | 依鲁替尼盐、其晶体、制备方法、药物组合物及应用 |
-
2016
- 2016-01-22 CN CN201610045061.9A patent/CN106995445B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104736178A (zh) * | 2012-06-04 | 2015-06-24 | 药品循环公司 | 布鲁顿酪氨酸激酶抑制剂的晶形 |
CN103694241A (zh) * | 2013-11-27 | 2014-04-02 | 苏州晶云药物科技有限公司 | Pci-32765的新晶型a及其制备方法 |
CN104327085A (zh) * | 2013-11-27 | 2015-02-04 | 苏州晶云药物科技有限公司 | Pci-32765的晶型a及其制备方法 |
CN103923084A (zh) * | 2014-01-29 | 2014-07-16 | 苏州晶云药物科技有限公司 | 几种新晶型及其制备方法 |
WO2015145415A2 (en) * | 2014-03-27 | 2015-10-01 | Perrigo Api Ltd. | Ibrutinib solid forms and production process therefor |
CN105085529A (zh) * | 2014-05-15 | 2015-11-25 | 广东东阳光药业有限公司 | 依鲁替尼新晶型及其制备方法 |
CN109776543A (zh) * | 2017-11-14 | 2019-05-21 | 上海医药工业研究院 | 依鲁替尼盐、其晶体、制备方法、药物组合物及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN106995445A (zh) | 2017-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104327085B (zh) | Pci-32765的晶型a及其制备方法 | |
CN105601635B (zh) | 巴瑞克替尼磷酸盐的a晶型、h晶型和i晶型及其制备方法 | |
WO2014016848A2 (en) | Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof | |
EP3272748A1 (en) | Pharmaceutical formulations comprising crystalline forms of (r)-7-chloro-n-(quinuclidin-3-yl)benzo(b)thiophene-2-carboxamide hydrochloride monohydrate | |
EP3842434B1 (en) | Crystal polymorph of 8-bromo-2-(1-methylpiperidin-4-ylamino)-4-(4-phenoxyphenylamino)pyrido[4,3-d]pyrimidin-5(6h)-one hydrochloride and method for preparing same | |
CN114174271B (zh) | 吡嗪-2(1h)-酮类化合物的c晶型和e晶型及其制备方法 | |
CN113651770B (zh) | 一种依帕司他晶型及其制备方法和应用 | |
CN106995445B (zh) | 一种布鲁顿酪氨酸激酶抑制剂晶型及其制备方法 | |
CN113966332A (zh) | Cdk9抑制剂的多晶型物及其制法和用途 | |
CN108976234B (zh) | 一种依鲁替尼和糖精的共无定型物及其制备方法 | |
CN103059013B (zh) | 达沙替尼一水合物的晶型及其制备方法 | |
EP3202772B1 (en) | Crystal of a complex of l-proline/sodium-glucose cotransporter 2 inhibitor | |
WO2017028802A1 (zh) | 5-[2, 6-二(4-吗啉基)-4-嘧啶基]-4-(三氟甲基)-2-吡啶胺二盐酸盐的晶型及其制备方法 | |
CN110804058B (zh) | 一种伊布替尼新晶型及其制备方法 | |
US11339164B2 (en) | Crystalline form E1 of larotrectinib ethanesulfonate | |
JP6871255B2 (ja) | ゲフィチニブの結晶形aを製造する方法 | |
CN111892590A (zh) | 一种哌柏西利新中间体及其晶型和制备方法 | |
CN107629048B (zh) | 一种酪氨酸激酶抑制剂的苹果酸盐的结晶形式及其制备方法 | |
CN113666892B (zh) | 一种恩格列净中间体的新晶型及其制备方法 | |
WO2009158450A1 (en) | Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, preparation and use thereof | |
CN111848580B (zh) | 含1,2,4-三嗪-3,5-二酮的喹啉类化合物的晶型及其制备方法和应用 | |
WO2024067085A1 (zh) | 一种细胞周期蛋白依赖性激酶(cdk4/6)抑制剂的枸橼酸盐、其晶型、制备方法和用途 | |
EP3351542B1 (en) | New crystal of piperazine compound | |
WO2009158446A2 (en) | Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, method of preparation and use thereof | |
CN106279170A (zh) | 5-氟-3-苯基-2-((1s)-1-(9h-嘌呤-6-基氨基)丙基)-3h-喹唑啉-4-酮的无水晶型及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Crystal form of Bruton tyrosine kinase inhibitor and preparation method thereof Effective date of registration: 20211224 Granted publication date: 20210803 Pledgee: Industrial and Commercial Bank of China Limited Feixian sub branch Pledgor: SHANDONG NEW TIME PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980016193 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20221028 Granted publication date: 20210803 Pledgee: Industrial and Commercial Bank of China Limited Feixian sub branch Pledgor: SHANDONG NEW TIME PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980016193 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Breton tyrosine kinase inhibitor crystal form and its preparation method Effective date of registration: 20221103 Granted publication date: 20210803 Pledgee: Industrial and Commercial Bank of China Limited Feixian sub branch Pledgor: SHANDONG NEW TIME PHARMACEUTICAL Co.,Ltd. Registration number: Y2022980020531 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |